Research
Hormonal
Tirzepatide (TZP) reduces HbA1c levels by −2.1% compared to insulin lispro U100 added to basal insulin.
TZP may be a more effective treatment option for lowering HbA1c in patients with T2D compared to insulin lispro.
StrongSupportsmedium confidence
In SURPASS-6, TZP was more effective than insulin lispro U100 added to basal insulin in reducing HbA1c levels at the study end (−2.1% vs. −1.1%, respectively).
Why this rating
Based on data from the SURPASS program, which includes human studies.
Source
Is Tirzepatide the New Game Changer in Type 2 Diabetes?
Giuseppe Lisco et al. · Endocrines · 2024
DOI 10.3390/endocrines5010005
reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →